Shahin Yarahmadi, Bagher Larijani, Ebrahim Javadi, Mohammad-Hassan Bastan Hagh, Mohammad Pajouhi, Reza Malekzadeh, Mahmood Mahmoudi, Aliereza Shafaei, Mohammad-Reza Mohajeri-Tehrani, Ali Rajabe, Mohammad Farshadi,
Volume 3, Issue 1 (16 2004)
Abstract
Celiac disease and typel diabetes mellirus have been linked to the same HLA markers and chromosomal loci, which may account for the concurrence of the two disorders in a significant number of patients. This study was designed to investigate the frequency of anti-gliadin antibodies, a marker for celiac disease, in diabetic patients.
Methods: In this study, 182 diabetic patients (52 with typel and 130 with type2 diabetes) were screened for anti-gliadin IgG by indirect immunofluorescence. Age range was 3-29.5 and 42-65 years for type 1 and type 2 diabetes groups.
Results: Anti-gliadin IgG was found in 1.9% and 1.5% of patients with type land type 2 diabetes. In Tehran, 0.02% of healthy blood donors have been reported to be seropositivitive for anti-gliadin IgG.
Conclusion: The prevalence of anti-gliadin seropositivity in type 1 and type 2 diabetics, was respectively 30 and 24 times higher than the general population of Tehran. This concurs with other reports indicating higher occurrence of celiac disease in diabetic populations. The rather low sensitivity and specificity (both around 80%) of the antigliadin antibody test has made it a suboptimal diagnostic test. However, it is quick and inexpensive and can be suitable for screening programs. We recommend the test in all at-risk populations including diabetics.
Farzad Hadaegh, Maryam Tohidi, Hadi Harati, Marjan Farshadi, Parisa Estaaneh,
Volume 4, Issue 1 (17 2004)
Abstract
Background: Diabetes type 1 is an autoimmune disease that is associated with other autoimmune disorders like Hashimoto thyroiditis. The purpose of this study was to determine the prevalence of autoimmune thyroid disease (ATD) in type 1 diabetic patients in the south of Iran (Bandar Abbas).
Methods: A cross-sectional study, was conducted 48 type 1 diabetics and 41 age and sex matched healthy controls were evaluated for the presence of ATD. Blood sample were collected from all of the subjects for the measurement of thyroid autoantobodies [anti thyroid peroxidase (anti-TPO) and anti thyroglobulin (anti-TG)], T3, T4, TSH, RT3U and HbA1c.
Results: Prevalence of positive anti-TPO and anti-TG was 29 % and 29% respectively in diabetic patients and 2% and 7% respectively in control group (P<0.05). The prevalence of ATD (positive anti TPO or anti TG) in diabetic patients and control subjects was 35% and 7% respectively (P<0.05). The prevalence of positive anti TPO and anti TG was higher in girls. There was no association between the prevalence of positive autoantibody and duration or age of onset of diabetes. 17.6% of diabetic patients with positive autoantibody had thyroid dysfunction (subclinical hypothyroidism and hyperthyroidism).
Conclusion: Regarding high prevalence of ATD in type 1 diabetic patients in Bandar Abbas (approximately 1 out of 3 patients), screening for ATD and thyroid dysfunction is recommended for all type 1 diabetic patiens and in those with positive autoantibody consecutively.
